ID | Age/Sex | FAB subtype | Fusion gene | Gene mutation | Karyotype | History of MDS/MPN | Prior lines of treatment | Previous HSCT | Extramedullary invasion | Pre-infusion disease burden (%) | Post-infusion disease burden (%)/efficacy evaluation | Bridged HSCT | CLL-1 Positivity (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 53/F | M5 | Negative | KRAS、TET2、ETV6 | 46, XX, -7, + mar | Yes | 6 | No | Yes | 16.43 | 71.78/NR | Yes | 50.2 |
2 | 44/M | M2 | N/A | NPM1、DNMT3A、IDH1、RUNX1、NRAS | N/A | No | 8 | No | No | 13.47 | 35.42/NR | Yes | 90.3 |
3 | 73/M | M5 | Negative | RUNX1、CEBPA、TET2、ASXL1、NRAS | 46, XY del (7), (q22q34) | Yes | 2 | No | No | 18.49 | 0.23/CRi | No | 82.8 |
4 | 29/M | M5 | Negative | CEBPA、FLT3、TET2 | N/A | No | 2 | No | Yes | 14.50 | 0/CRi | Yes | 92.3 |
5 | 47/F | M5 | Negative | Negative | Normal | No | 8 | Yes | No | 83.55 | 86.51/NR | No | 89.6 |
6 | 49/F | M5 | MLL-AF9 | ZRSR2 | N/A | No | 2 | No | No | 28.36 | 0/CR | No | 97.6 |
7 | 43/F | M2 | Negative | Negative | N/A | No | 10 | Yes | No | 7.12 | 0/CRi | No | 82.2 |
8 | 39/F | M5 | Negative | RUNX1, U2AF1 | 46, XX, + 1, der(1;7) | Yes | 4 | Yes | No | 10.24 | 2.11/CRi | Yes | 66.9 |
9 | 18/F | M2 | Negative | RUNX1、FLT3 | Normal | No | 6 | Yes | No | 3.09 | 0/CRi | Yes | 80.6 |
10 | 29/M | M5 | Negative | Negative | Normal | No | 3 | Yes | No | 22.80 | 3.02/CRi | Yes | 87.6 |